Abstract

Anass Lahlou*, Karim El Hammiri, Yassine Moubadi, Tarik El Mountassir, Moncef Boufettal, Reda Allah Bassir, Mohamed Kharmaz, Moulay Omar Lamrani and Mohamed Saleh Berrada

ABSTRACT

The synovial sarcoma is a rare tumor of bad prognosis. It accounts for 5 to 10% of soft tissue sarcomas. Histology, immunohistochemistry and molecular biology are indispensable for the diagnostic. Surgery is the primary treatment modality while radiotherapy and chemotherapy allow greater local control. The evolution is marked by the occurrence of local recurrence and pulmonary metastases especially. We report our study of 20 cases Synovial, collected between 2010 and 2017. The objective of our work is to show the great variety of diagnostic, therapeutic and prognostic elements within a rare pathology and often poorly considered from a nosological level. The long-term follow-up has not been clarified because most patients are lost to view as well as the problem of accessibility to care, cause of a late diagnosis and therefore an unfavorable prognosis. It requires multidisciplinary coordination and new therapeutic approaches pave the way for better prospects.